Global Diabetes Pen Market Size was USD 18.70 Billion in 2025, this report covers Market growth, trend, opportunity and forecast from 2026-2032

The Diabetes Pen market is characterized by intense competition, with a mix of established leaders and innovative challengers driving technological and strategic evolution.

1. Novo Nordisk A/S:

   Novo Nordisk A/S occupies a leadership position in the global diabetes pen market, with a broad portfolio that spans disposable pens, durable reusable pens, and connected smart pen systems. The company leverages its strong insulin and GLP-1 franchise to secure formulary access and preferred product placement, which reinforces its dominance in key regions such as North America, Europe, and parts of Asia. Its extensive relationships with endocrinologists, diabetologists, and large hospital networks give it structural advantages in both penetration and retention of patients.

   In 2025, Novo Nordisk’s diabetes pen-related revenue is estimated at USD 5.60 billion with a global market share of approximately 29.95% . These figures indicate that the company commands nearly one-third of the diabetes pen segment, underscoring its scale efficiencies in manufacturing, distribution, and R&D. This level of concentration enables Novo Nordisk to negotiate favorable pricing with payers while still investing aggressively in device innovation and patient support programs.

   Novo Nordisk’s competitive differentiation stems from its integrated drug–device approach, where insulin and GLP-1 formulations are co-developed with pen platforms to optimize dosing accuracy, injection force, and patient usability. The company is also pushing ahead with connected pens and digital dose-tracking solutions that link with mobile applications and cloud-based diabetes management platforms. For investors and strategists, this integration of pharmacotherapy and digital health generates high switching costs for patients and clinics, strengthening brand stickiness and long-term revenue visibility.

2. Sanofi:

   Sanofi is a major global player in insulin therapy and holds a significant position in the diabetes pen market through its basal and rapid-acting insulin portfolios. Its insulin pens are widely adopted in Europe, Latin America, and emerging markets, where they benefit from longstanding procurement relationships and national reimbursement schemes. The company’s emphasis on reliability, ease of use, and dose precision has helped it remain a preferred supplier in public tenders and large integrated delivery networks.

   For 2025, Sanofi’s diabetes pen business is projected to generate revenue of USD 3.20 billion with an estimated market share of 17.11% . This scale places Sanofi firmly in the top tier of competitors while still leaving headroom relative to the market leader. The revenue and share profile reflects strong penetration in mature insulin markets but more modest exposure to premium-priced digital or smart pen ecosystems, which is a strategic opportunity for expansion.

   Sanofi’s strategic advantages lie in its clinical legacy in insulin therapy, its broad geographic footprint, and its experience in navigating complex reimbursement environments. The company is working to differentiate further through improvements in pen ergonomics, dose visibility, and needle technology, as well as through partnerships in connected diabetes management platforms. Compared with peers, Sanofi leverages its diversified pharmaceutical portfolio to cross-subsidize device innovation and support competitive tender pricing, positioning it as a resilient and cost-effective supplier to health systems.

3. Eli Lilly and Company:

   Eli Lilly and Company is a central competitor in the diabetes pen landscape, anchored by its strong insulin portfolio and growing presence in incretin-based therapies. The company has developed a range of disposable and reusable insulin pens that focus on simple dose dialing, low injection force, and consistent reliability. Its presence is particularly strong in North America and select European markets, where it competes actively for formulary access and patient share.

   In 2025, Eli Lilly’s diabetes pen-related revenue is estimated at USD 2.60 billion with a market share of about 13.92% . This footprint signifies a robust but more focused position compared with the two largest incumbents, suggesting both strong brand recognition and opportunities for accelerated growth through innovation. The revenue scale supports sustained investment in next-generation delivery platforms that align with Lilly’s fast-growing diabetes and metabolic drug pipeline.

   Eli Lilly’s competitive differentiation centers on its innovation capability in diabetes pharmacology and its ability to integrate novel therapies with user-friendly delivery devices. The company is actively exploring connected pen technologies that integrate dosing data with digital coaching and glucose monitoring systems. Strategically, its emphasis on outcomes-based value propositions and real-world evidence allows it to pitch its pen ecosystems not just as devices but as components of broader glycemic control programs, providing an edge in negotiations with payers and integrated care providers.

4. Biocon Ltd:

   Biocon Ltd plays a pivotal role in the diabetes pen market, particularly in biosimilar insulin segments and cost-sensitive geographies. The company has developed insulin pens that pair with its biosimilar insulin products, targeting both domestic markets in India and international markets where payers prioritize affordability. Its strategy is centered on offering clinically comparable alternatives to originator products at competitive price points, thereby expanding access for large patient populations.

   For 2025, Biocon’s revenue from diabetes pens is projected at USD 0.70 billion with a market share of approximately 3.75% . This footprint indicates meaningful penetration in emerging and middle-income markets and a growing presence in regulated markets through biosimilar partnerships. The combination of moderate scale and competitive pricing positions Biocon as a disruptive challenger rather than a volume leader, with upside potential as biosimilar adoption accelerates.

   Biocon’s strategic advantage lies in its biologics and biosimilars manufacturing capabilities, which enable it to deliver high-quality insulin formulations compatible with robust yet affordable pen devices. The company partners with global firms for co-marketing and distribution in certain regions, leveraging their commercial infrastructure while retaining manufacturing control. Compared with multinational incumbents, Biocon competes primarily on cost-efficiency and regulatory agility, allowing it to capture tender-based contracts and penetrate markets where budget impact is the dominant decision criterion.

5. Medtronic plc:

   Medtronic plc is best known for its leadership in insulin pumps and continuous glucose monitoring, but it also contributes to the broader insulin delivery ecosystem that includes pen solutions in certain markets. While diabetes pens are not its primary revenue driver, Medtronic’s involvement in pen-compatible digital platforms and decision-support tools influences how patients and clinicians evaluate delivery modalities. Its digital health infrastructure positions the company as a systems integrator across multiple diabetes technologies.

   In 2025, Medtronic’s direct revenue attributable to diabetes pen-related solutions is estimated at USD 0.40 billion with a market share of around 2.14% . These figures suggest a niche but strategically relevant presence, especially where patients transition between pens and pump therapy or use pens as backup systems. The relatively modest share underscores that Medtronic’s competitive strength in diabetes care lies more in advanced hardware and integrated systems than in standalone pen volumes.

   Medtronic differentiates itself through its data platforms, clinical decision-support algorithms, and integration of insulin dosing data with CGM trends. This capability allows the company to influence treatment pathways and potentially steer eligible patients towards its pump systems while still supporting pen users through digital tools. For strategic planners, Medtronic’s role in the diabetes pen market is less about sheer unit sales and more about shaping the connected-care environment in which pens, pumps, and monitoring technologies coexist.

6. Ypsomed Holding AG:

   Ypsomed Holding AG is a specialized device manufacturer with strong capabilities in pen injectors, autoinjectors, and related subcutaneous drug delivery technologies. In the diabetes pen market, Ypsomed often partners with pharmaceutical companies to supply pen platforms that are branded under the pharma partner’s name. This business-to-business model makes Ypsomed a critical, albeit sometimes less visible, enabler of global diabetes pen deployment.

   For 2025, Ypsomed’s diabetes pen-related revenue is projected at USD 0.50 billion with an estimated market share of 2.67% . This share reflects its role as an upstream technology provider rather than a direct-to-patient brand leader. The revenue base demonstrates substantial scale in pen manufacturing and engineering services, with exposure across multiple therapeutic brands and regions.

   Ypsomed’s strategic advantages include its modular platform architecture, precision engineering, and capabilities in large-scale, high-quality manufacturing. The company invests heavily in human factors engineering to ensure pens are intuitive, safe, and compatible with varying patient dexterity levels. Compared with integrated pharma-device companies, Ypsomed competes on design flexibility, speed to market, and the ability to customize pen systems for different drug formulations, making it an attractive partner for both originator biologics and biosimilar developers entering the diabetes segment.

7. Owen Mumford Ltd:

   Owen Mumford Ltd is a UK-based medical device company with a strong legacy in injection systems, including pen injectors and safety lancets for diabetes care. Within the diabetes pen market, the company predominantly operates as an OEM and technology partner, supplying pen platforms and components that are often rebranded by pharmaceutical clients. Its products emphasize patient comfort, ergonomic design, and consistent dose delivery.

   In 2025, Owen Mumford’s diabetes pen-related revenue is estimated at USD 0.25 billion with a market share of about 1.34% . This indicates a specialized but smaller-scale presence compared with the largest device manufacturers, yet significant enough to influence design and safety standards in the sector. The company’s revenue base supports ongoing investment in needle technology and pen design improvements, particularly for self-administration use cases.

   Owen Mumford differentiates itself through its focus on user-centered design and safety engineering, such as reduced injection pain, improved grip surfaces, and intuitive dose setting. The company’s business model relies on building long-term partnerships with pharmaceutical manufacturers that require reliable, high-quality delivery systems for insulin and other injectable therapies. Relative to larger diversified medtech firms, Owen Mumford competes on agility, customization, and specialized expertise in injection technologies rather than on sheer manufacturing volume.

8. Becton, Dickinson and Company:

   Becton, Dickinson and Company (BD) is a global leader in injection and infusion technologies, with a substantial footprint in needles, syringes, and pen components used in diabetes care. In the diabetes pen market, BD’s presence is both direct, via pen needles and certain delivery systems, and indirect, through supplying critical components to other pen manufacturers. Its products are widely used by patients worldwide for insulin administration and blood glucose management.

   For 2025, BD’s diabetes pen-related revenue is projected at USD 0.80 billion with an estimated market share of 4.28% . These numbers highlight BD’s role as a key infrastructure player in the insulin delivery value chain. While its branded pen platforms may not always be the primary therapy identifier for patients, its components and needles underpin a significant portion of global pen-based insulin delivery.

   BD’s strategic advantages include world-class manufacturing capacity, deep expertise in needle and micro-engineering, and a broad customer base that spans hospitals, pharmacies, and home-care channels. The company focuses on improving injection safety, reducing needle-stick injuries, and enhancing patient comfort, which collectively support adherence and long-term therapy success. Compared with more therapy-focused companies, BD’s diversified portfolio and component-focused model make it a relatively stable and indispensable supplier across multiple diabetes pen brands and regions.

9. F. Hoffmann-La Roche Ltd:

   F. Hoffmann-La Roche Ltd has historically been influential in diabetes care through its glucose monitoring systems and digital diabetes management solutions. While it is not a top-volume manufacturer of insulin pens themselves, Roche’s platforms increasingly interface with pen-based therapy, particularly through connected health applications and data management tools. This ecosystem integration places Roche as a key digital stakeholder in how pen therapy is monitored and optimized.

   In 2025, Roche’s revenue tied directly to diabetes pen-related solutions and integrated platforms is estimated at USD 0.35 billion with a market share of around 1.87% . The figures reflect a selective but strategically relevant role focused on value-added services rather than core pen manufacturing. Its revenue base in this area supports investments in application software, data analytics, and interoperability features that enhance the clinical value of pen-based insulin regimens.

   Roche’s competitive differentiation stems from its digital health capabilities, strong brand recognition in glucose monitoring, and focus on integrated diabetes management. By enabling data capture from pens, meters, and other devices, it helps clinicians and patients track dosing behavior, glycemic variability, and adherence trends. Compared with pure-play pen manufacturers, Roche competes in the layer above the device, targeting improved clinical outcomes and workflow efficiency through software and data integration, which can indirectly influence pen selection and treatment pathways.

10. Wockhardt Ltd:

    Wockhardt Ltd is an India-based pharmaceutical company active in insulin and diabetes care, with a presence in both domestic and selected international markets. In the diabetes pen market, Wockhardt focuses on providing cost-effective insulin pens that address the affordability challenges in low- and middle-income regions. Its strategy involves bundling insulin formulations with user-friendly pens designed for mass-market adoption.

    For 2025, Wockhardt’s diabetes pen revenue is projected at USD 0.20 billion with an estimated market share of 1.07% . This scale underscores a modest but meaningful role in regional markets where budget constraints dictate therapy choices. The company’s share suggests potential for expansion as insulin usage and diagnosis rates rise in emerging economies, provided it can maintain quality and regulatory compliance.

    Wockhardt’s strategic advantages include its cost-competitive manufacturing base, familiarity with local regulatory frameworks, and distribution networks across South Asia and select global markets. The company differentiates itself by positioning its pens as affordable alternatives to multinational brands, often targeting public sector tenders and large pharmacy chains. Relative to larger incumbents, Wockhardt competes on price accessibility and local presence rather than on advanced digital features or premium pen designs.

11. Berlin-Chemie AG:

    Berlin-Chemie AG, a company within a larger European pharmaceutical group, participates in the diabetes pen market primarily through its insulin and antidiabetic portfolios in Central and Eastern Europe. The company offers insulin pens that are tailored to regional prescribing patterns and reimbursement systems, often focusing on reliable and straightforward devices that meet local clinical requirements. Its strong country-level relationships with diabetology centers enhance its visibility in targeted markets.

    In 2025, Berlin-Chemie’s diabetes pen-related revenue is estimated at USD 0.22 billion with a market share of about 1.18% . The figures reflect a regionally focused but strategically important presence, especially in markets where Western European and global multinationals face pricing and access challenges. This footprint gives Berlin-Chemie leverage in shaping local standard-of-care practices for pen-based insulin therapy.

    Berlin-Chemie’s competitive differentiation arises from its regional expertise, strong relationships with healthcare professionals, and ability to adapt its offerings to the regulatory and economic contexts of Central and Eastern Europe. The company often emphasizes training, patient education, and support materials alongside its pens, building loyalty among prescribers and patients. Compared with global giants, Berlin-Chemie competes through local fit, agility in market access, and a focused geographic strategy rather than global scale.

12. Emperra GmbH E-Health Technologies:

    Emperra GmbH E-Health Technologies is an innovation-driven company specializing in connected diabetes solutions, including smart insulin pens and digital platforms. In the diabetes pen market, Emperra focuses on transforming conventional pens into data-generating devices that support telemedicine, adherence monitoring, and data-driven therapy optimization. Its products target both technologically engaged patients and healthcare providers looking to integrate real-time dose data into clinical decision-making.

    For 2025, Emperra’s revenue from smart diabetes pens and associated digital services is estimated at USD 0.10 billion with a market share of approximately 0.53% . Although this represents a small portion of the overall market, the company’s role is strategically important in the rapidly expanding connected pen subsegment. Its share demonstrates early-mover traction in digital insulin delivery solutions that are increasingly valued by payers and providers focused on outcomes.

    Emperra’s strategic advantages include its software development expertise, cloud platform capabilities, and focus on interoperability with electronic health records and glucose monitoring systems. The company differentiates itself from traditional pen manufacturers by prioritizing data analytics, user dashboards, and remote care features over large-scale hardware production. This makes Emperra an attractive partner or acquisition target for larger pharma or medtech players that seek to accelerate their entry into connected diabetes pens without building digital infrastructure from scratch.

13. Hindustan Syringes and Medical Devices Ltd:

    Hindustan Syringes and Medical Devices Ltd (HMD) is a major Indian manufacturer of syringes, needles, and other injection devices, with growing activity in pen components and related diabetes delivery products. In the diabetes pen market, HMD’s role is largely as a high-volume, cost-efficient supplier of needles and certain device elements used with insulin pens. Its presence is strongest in South Asia, with expanding exports to other emerging markets.

    In 2025, HMD’s diabetes pen-related revenue is projected at USD 0.18 billion and its market share at approximately 0.96% . This footprint reflects its significant contribution to the supply of affordable injection solutions, even though it is not a leading branded pen manufacturer. The revenue base underscores sustained demand for pen needles and ancillary products that support daily insulin administration at scale.

    HMD’s competitive strengths include its low-cost manufacturing platform, extensive distribution network, and track record of meeting high-volume tenders for public health systems. The company differentiates itself through affordability and reliability, focusing on basic but essential components that enable widespread use of insulin pens in resource-constrained environments. Compared with technology-heavy competitors, HMD’s strategy centers on scale, cost-effectiveness, and operational efficiency rather than advanced connectivity or premium device features.

14. Haselmeier GmbH:

    Haselmeier GmbH is a specialized developer and manufacturer of injection devices, including pen injectors widely used for insulin and other biologics. In the diabetes pen market, Haselmeier primarily operates as a partner to pharmaceutical and biotech companies, offering customizable pen platforms that can be adapted to specific formulations and branding requirements. Its focus on engineering excellence and user-centric design makes it a key innovator in pen mechanics and usability.

    For 2025, Haselmeier’s diabetes pen-related revenue is estimated at USD 0.28 billion with a market share of about 1.50% . The company’s share highlights a meaningful role as an upstream design and manufacturing partner, with exposure across multiple therapy brands and geographies. This diversified customer base supports resilience against single-product or single-market volatility.

    Haselmeier’s strategic differentiation derives from its proprietary pen platforms, expertise in combination product development, and ability to deliver tailored solutions quickly. It invests in human factors research to ensure its devices align with patient capabilities, including elderly users and those with limited dexterity. Compared with pharmaceutical incumbents that in-source device development, Haselmeier competes on design flexibility, technical depth, and collaborative development models, which can accelerate time to market for new insulin and GLP-1 pen products.

15. Terumo Corporation:

    Terumo Corporation is a diversified Japanese medical technology company with strong capabilities in syringes, needles, and infusion systems, and a growing presence in pen injectors for chronic diseases including diabetes. In the diabetes pen market, Terumo participates through both its own pen devices in certain regions and through supplying components and technologies to pharmaceutical partners. The company leverages its precision manufacturing and quality standards to compete in regulated markets worldwide.

    In 2025, Terumo’s diabetes pen-related revenue is projected at USD 0.46 billion with an estimated market share of 2.46% . These figures indicate a solid mid-tier position in the device and component segment of the market, with significant potential for expansion as injectable diabetes therapies proliferate. The revenue base supports continued investment in R&D aimed at improving device safety, dose accuracy, and patient comfort.

    Terumo’s strategic advantages include its stringent quality systems, global regulatory experience, and strong reputation among clinicians for reliable injection products. The company differentiates itself through fine-gauge needle technology, smooth injection performance, and compatibility with a wide range of insulin formulations. Compared with smaller device firms, Terumo benefits from broader scale and distribution, while relative to pharma-led competitors it offers neutral, platform-based solutions that can be adopted by multiple insulin and GLP-1 manufacturers seeking high-quality pen technologies.